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Available online 13 May 2016Objective: To investigate effects of coldweather spells on incidence of cardiovascular disease (CVD), and potential
effect modiﬁcation of socio-demographic, clinical, behavioural and environmental exposures.
Methods: Data from two prospective studies were analysed: the British Regional Heart Study (BRHS), a
population-based study of British men aged 60–79 years, followed for CVD incidence from 1998–2000 to
2012; and the PROSPER study of men and women aged 70–82 recruited to a trial of pravastatin vs placebo
from 1997 to 9 (followed until 2009). Cold spells were deﬁned as at least three consecutive days when daily
mean temperature fell below the monthly 10th percentile speciﬁc to the closest local weather station. A time-
stratiﬁed case-crossover approach was used to estimate associations between cold spells and CVD events.
Results: 921 of 4252men fromBRHS and 760 of 2519 participants fromPROSPER suffered aﬁrst CVD event during
follow-up. More CVD events were registered in winter in both studies. The risk ratio (RR) associated with cold
spells was statistically signiﬁcant in BRHS (RR= 1.86, 95% CI 1.30–2.65, p b 0.001), and independent of temper-
ature level: resultswere similarwhether eventswere fatal or non-fatal. Increased riskwas particularlymarked in
BRHS for ever-smokers (RR of 2.44 vs 0.99 for never-smokers), inmoderate/heavy drinkers (RR 2.59 vs 1.41), and
during winter months (RR 3.28 vs 1.25). No increased risk was found in PROSPER.
Conclusions:AlthoughCVD riskswere higher inwinter in both BRHS and PROSPER prospective studies, cold spells
increased risk of CVD events, independently of cold temperature, in the BRHS only.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
Cold spell
Outdoor temperature
Winter deaths
Cardiovascular disease
Prospective study
Older people1. Background
Cardiovascular disease (CVD) is the most common cause of death
globally, remaining a considerable burden both in terms of health and
costs [1]. As in many countries, CVD mortality in the UK exhibits a
marked seasonal variation; more people die during the winter months
(December–March) than in other periods of the year and the majority
of deaths occur among those aged 75 and over [2,3]. This seasonal
variation in death rates has been mainly attributed to cold weather
and fall in temperature, which can alter vulnerability to speciﬁc
diseases, in particular myocardial infarction, stroke and respiratory in-
fection (especially inﬂuenza) [4–7]. However, uncertainty still exists
about the range in temperature which produces an increased risk of
CVD and other health outcomes, [8,9] since effects of both extremely
cold days [10,11] and moderately cold days [8] on mortality have been
demonstrated. To date, there is neither an established deﬁnition of aland Ltd. This is an open access articlcold day nor a precise deﬁnition of the period for which a cold spell
(e.g. two or more consecutive cold days) should last for detrimental
health effects [9]. Less frequently, cold spells in the UK can also occur
during the non-winter months (May–November) [12], with lowest
minimum and maximum temperatures in England of−2 °C and 9 °C
in August [13].
A much debated question is which people are more susceptible to
cold temperature or cold spells, and the relative importance of individ-
ual characteristics such as age, previous chronic conditions, low income
and cold homes [7,14–17]. The elderly have been long considered more
susceptible to cold weather [5], but the evidence is not consistent [17],
For example, the odds of death in the elderly may be signiﬁcant only if
associated with cold spells, but not a linear decrease in temperature
[15]. In other studies the statistical power to examine evidence for effect
modiﬁcation was low and evidence for differences in effect of cold
temperature on cardiovascular mortality according to obesity, smoking
habit, alcohol intake, and hypertension was not found [16].
Therefore, the aims of this study are threefold: (i) to investigate
the effect of cold spells on cardiovascular events during 1997–2012e under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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data from two large prospective studies of older adults; (ii) to explore
whether the effect of cold spells is modiﬁed by established cardiovascu-
lar risk factors (e.g. age and smoking) and previously unexplored
individual characteristics (e.g. physical activity score, central heating
and double glazing in the house); (iii) to explore whether the effect of
cold spell is independent from average temperature over periods up
to 6 days previously.
We carried out a primary analysis on men from an established UK
population-based study, the British Regional Heart Study (BRHS) [18],
and secondarily on participants of the PROspective Study of Pravastatin
in the Elderly at Risk (PROSPER) [19,20] recruited from Glasgow (UK),
Cork (Republic of Ireland), Leiden (The Netherlands) and the surround-
ing areas.
2. Methods
2.1. Methods and participants
Participants from BRHS and PROSPER provided informed written
consent, which was performed in accordance with the principles of
the Declaration of Helsinki. The designs of both BRHS [21] and
PROSPER [19,20], which are both prospective studies of several thou-
sand participants with cardiovascular disease as their key endpoints,
have been previously described in detail and included in this work as
supplementary material (Supplementary File 1 – BRHS and PROSPER
methods and participants).
2.2. Case ascertainment and follow-up
The BRHS cohort was followed-up from Jan. 1998–March 2000 until
the endof 2012,while the PROSPER participantswere followed-up from
December 1997–May 1999 until the end of June 2009. The events
considered during the corresponding study periods for the two studies
were fatal or nonfatal stroke and CHD death or non-fatal myocardial
infarction (MI). The deﬁnitions of non-fatal/fatal stroke and CHD
death/non-fatal MI are reported in supplementary material (Supple-
mentary File 1 — Deﬁnition of fatal and non-fatal CVD events).
2.3. Climatic data and deﬁnition of cold spell
Mean temperature of the day for the study towns was provided by
the national meteorological ofﬁces (Supplementary File 1 — Climatic
data). The deﬁnition of cold spell used in this study was derived from
daily mean temperatures and related to spells which were, for at least
3 or 4 consecutive days, below the 10th percentile for that geographical
location for the speciﬁc month of the year (for details see Supplementa-
ry File 1 — Deﬁnition of cold spell).
2.4. Statistical methods
Firstly, baseline characteristics of BRHS and PROSPER participants
were compared between those who did or did not experience the CVD
events (non-fatal or fatal) during follow-up.
Then, monthly descriptive statistics of number of events were calcu-
lated. Average mean temperatures, and number of cold spells of at least
3 and 4 consecutive days were calculated by month, for both BRHS and
PROSPER separately, and during event days and control days (deﬁned
below).
Only participants who suffered an event were included in subse-
quent analysis, and short-term associations between cold spell and
CVD events were assessed using a time-stratiﬁed case-crossover
approach, widely used in environmental epidemiology [22]. A case-
crossover study can be seen as a self-matched case–control study: for
each individual, exposure data are collected for the “case” day (that is,
the day of the cardiovascular event) and a set of “control” days thatwere not associated with the event of interest. The “control” days
were selected by using the same days of the week of the same month
and year [23]. For each “case” and “control” daywedeterminedwhether
the speciﬁc day and days preceding were cold days.
We then compared cases with their set of controls using conditional
logistic regression. The outcome was a binary variable (case or control)
as was the exposure variable (day of event being part of a cold spell
or not). Therefore, the odds ratios from the conditional-logistic-
regression model can be interpreted as risk ratios (RRs). By design, the
analyses are adjusted for long-term changes in environmental expo-
sures, for day of the week, and for all participant characteristics that
are expected to remain stable over a 1-month period (e.g., smoking
status).
We reported results for 7 different outcomes: (1) all causes of death;
(2) fatal events (fatal stroke or CHD death); (3) CHD death; (4) fatal
stroke; (5) earliest of fatal/non-fatal stroke or CHD death/non-fatal
MI; (6)MI events (earliest nonfatalMI or CHDdeath); (7) stroke events
(earliest non-fatal or fatal) stroke. For each outcome type, only the ﬁrst
event of the relevant typewas included. Results are presented separate-
ly for the two studies but we also carried out a ﬁxed effects meta-
analysis to pool results.
We made use of the wide range of individual risk factors in BRHS to
examine interaction effect between cold spells and these risk factors.
3. Results
3.1. Participants' characteristics
In the BRHS, 4252men out of 5875men (72.4%) were alive at 01/01/
1998 and participated at the 20 year follow-up examination and survey.
3977 men (67.7%) did not change town of residence during the study
period 1998–2012. Participants were followed for a median of
12.7 years (inter-quartile range 8.7, 13.5). The BRHS participants' char-
acteristics are shown in Table 1a, according to whether or not they later
experienced CVD events (921 participants: 23.2%, and 521 (13.1%) fatal
events (fatal stroke or CHD death). The baseline characteristics of the
study participants for PROSPER are reported in Table 1b. In the
PROSPER study non-fatal events were available for the Glasgow Centre
only: 760 out of 2520 participants (30.2%) had development of CVD
(earliest of fatal or non-fatal stroke or non-fatal MI or CHD death).
Considering all PROSPER cohorts (Glasgow plus Cork and Leiden), the
number of CVD deaths (fatal stroke or CHD death) registered during
the follow up period (median = 10.3 years (IQR 6.9 to 10.7) was 810
out of 5804 (14%).
PROSPER participants in comparison with BRHS participants (see
Table 1a vs Table 1b) were about 5 years older, with a higher CVD
prevalence, but also less likely to have diabetes, to be smokers, or to
drink alcohol. PROSPER participants were also more likely to live alone
and use aspirin, beta-blockers, ACE-inhibitors, diuretics, calcium chan-
nel blockers and nitrates. Owing to the nature of the PROSPER study,
50% were initially assigned to statins, while less than 10% of BRHS
participants took statins at baseline.
3.2. Monthly distribution of events, temperatures and cold spells
During the study period, mortality from all causes and from CVD
(fatal stroke or CHD death) was highest during the winter months
(December–March) in both BRHS (Table 2a) and PROSPER (Table 2b)
cohorts, see also eFigure 1 (Supplementarymaterial). The excesswinter
mortality (EWM) from all causes of death was 18% in both studies, but
the EWM from CVD was higher (36% in BRHS and 23% in PROSPER).
Mean temperatures on event or control days (where ‘events’ were
ﬁrst events of any type; ie. outcome5 as deﬁned in theMethods section)
were lowest from December to March in both BRHS (Table 2a) and
PROSPER (Table 2b).
Table 1a
BRHS participant's characteristics (January 1998–March 2000) subdivided by thosewhodid or did not experience CVD events (non-fatal or fatal) during follow-up (January 1998–Decem-
ber 2012).
Have had fatal/non-fatal CVD event
(non-fatal/fatal stroke or non-fatal MI/CHD death)
CVD death (fatal stroke or CHD death)
Yes (n = 921) No (n = 3056) Yes (n = 521) No (n = 3456)
Demographic and background characteristics
Age (years), mean (SD) 70.4(5.5) 68.2(5.4) 71.8(5.2) 68.2(5.4)
Social class (manual), n(%) 488(53.2) 1565(51.2) 289(55.6) 1764(51.1)
Physical health
Prevalence of non-fatal stroke or MI at baseline, n(%) 158(17.2) 193(6.3) 115(22.1) 236(6.8)
BMI, mean (SD) 27.1(3.8) 26.9(3.7) 27.0(3.8) 27.0(3.7)
Diabetes, n(%) 137(14.9) 309(10.1) 82(15.7) 364(10.5)
Lung function (FEV1/FVC b70%), n(%) 242(26.7) 792(26.2) 151(29.5) 883(25.8)
Behaviour
Physical activity score at baseline
Inactive, n(%) 145(16.5) 301(10.2) 97(19.7) 349(10.4)
Occasional/Light, n(%) 380(43.3) 1228(41.5) 208(42.3) 1400(41.9)
From moderately to vigorously active, n(%) 352(40.1) 1427(48.3) 187(38.0) 1592(47.7)
Smoking
Never, n(%) 233(25.4) 908(29.7) 113(21.8) 1028(29.8)
Former, n(%) 548(59.8) 1754(57.5) 316(60.9) 1986(57.5)
Current, n(%) 136(14.8) 391(12.8) 90(17.3) 437(12.7)
Alcohol consumption
None, n(%) 114(12.6) 287(9.5) 66(13.0) 335(9.8)
Occasional (b1 drink/week), n(%) 276(30.6) 775(25.7) 158(31.1) 893(26.2)
Light (1–15/week), n(%) 344(38.1) 1363(45.3) 196(38.6) 1511(44.3)
Moderate/regular (16–42/weeks), n(%) 133(14.7) 480(15.9) 68(13.4) 545(16)
Heavy (N42/week), n(%) 29(3.2) 92(3.1) 16(3.1) 105(3.1)
Unclassiﬁed, n(%) 7(0.8) 15(0.5) 4(0.8) 18(0.5)
House/accommodation
Owner occupier, are you:
An owner occupier, n(%) 745(83.7) 2621(87.9) 408(81) 2958(87.8)
Does your home have
Central heating (yes), n(%) 807(92.0) 2742(93.5) 447(90.9) 3102(93.5)
Double glazing (yes/in part), n(%) 517(85.9) 1648(85.4) 286(83.6) 1879(85.8)
Personal circumstances
Marital status
Married (yes), n(%) 721(81.8) 2525(84.9) 392(78.7) 2854(85)
Working status
Retired, n(%) 778(86.6) 2351(78.6) 467(92.5) 2662(78.7)
Living conditions
Living alone, n(%) 128(14.3) 325(11) 88(17.3) 365(10.9)
Car ownership (Yes/No)
Yes, n(%) 705(78.4) 2549(84.5) 370(72.7) 2884(84.7)
Use of medication (yes)
Anti-coagulants, Warfarin, n(%) 44(4.8) 73(2.4) 32(6.1) 85(2.5)
Aspirin, n(%) 358(39.1) 719(23.6) 223(43.2) 854(24.8)
Beta-adrenoceptor blocking drugs, n(%) 150(16.3) 389(12.7) 95(18.2) 444(12.8)
Statin, n(%) 101(11.0) 202(6.6) 63(12.1) 240(6.9)
ACE-Inhibitors, n(%) 7(0.8) 9(0.3) 5(1.0) 11(0.3)
A-II receptor antagonists, n(%) 5(0.5) 16(0.5) 3(0.6) 18(0.5)
Diuretics, n(%) 181(20.5) 356(10.9) 128(25.9) 409(11.2)
Calcium channel blockers, n(%) 178(20.1) 402(12.4) 118(23.8) 462(12.7)
Nitrates, n(%) 138(15.6) 236(7.3) 92(18.6) 282(7.7)
Other antihypertensive, n(%) 2(0.2) 7(0.2) 2(0.4) 7(0.2)
Blood glucose lowering: insulin, n(%) 17(1.9) 26(0.8) 10(2.0) 33(0.9)
Blood glucose lowering: oral hypoglycaemics, n(%) 54(6.1) 102(3.1) 35(7.7) 121(3.3)
Established CVD risk factors
Systolic blood pressure, mm Hg, mean (SD) 153.3(26.1) 147.8(23.6) 154.3(27.5) 148.3(23.7)
Diastolic blood pressure, mm Hg, mean (SD) 85.7(12.2) 85.0(10.8) 85.3(12.9) 85.1(10.9)
Total cholesterol, mmol/L, mean (SD) 6.0(1.1) 6.0(1.1) 6.0(1.0) 6.0(1.1)
LDL-cholesterol, mmol/L, mean (SD) 3.9(1.0) 3.9(1.0) 3.9(1.0) 3.9(1.0)
HDL-cholesterol, mmol/L, mean (SD) 1.3(0.3) 1.3(0.3) 1.3(0.3) 1.3(0.3)
Triglycerides, mmol/L, mean (SD) 1.9(1.1) 1.8(1.1) 1.9(1.1) 1.8(1.1)
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during winter (December–March). More cold spells occurred during
follow-up of BRHS participants (1998–2012) than of PROSPER partici-
pants (1997–2009). During the BRHS follow-up cold spells were more
common during events days than control days (p b 0.001 for BRHS),
while there was no evidence of a difference in PROSPER (p = 0.933
for PROSPER).3.3. Associations (main effect) between cold spells and cardiovascular events
Using the time-stratiﬁed case-crossover approach, associations
were noted between cold spells of ≥3 days and ≥4 days and some
end-points (CVD mortality and development of CVD events) in the
BRHS study (Table 3). Associations were found between cold spells
of ≥3 days and ≥4 days and the following end-points: (i) fatal events
Table 1b
PROSPER participant's characteristics (December 1997 –May1999) subdivided by thosewhodid or did not experience CVD events (non-fatal or fatal) during follow-up (December 1997–
June 2012).
Have had fatal/non-fatal CVD event
(non-fatal/fatal stroke or non-fatal MI/CHD death),
Glasgow participants
CVD death (fatal stroke or CHD death), all
PROSPER participants
Yes (n = 760) No (n = 1760) Yes (n = 810) No (n = 4994)
Demographic and background characteristics
Age (years), mean (SD) 75.9 (3.4) 75.0 (3.3) 76.3 (3.4) 75.2 (3.3)
Social class (manual), n(%) n.a. n.a. n.a. n.a.
Physical health
Prevalence of non-fatal stroke or MI at baseline, n(%) 185 (24.3) 278 (15.8) 223 (27.5) 756 (15.1)
BMI, mean (SD) 26.8 (4.4) 26.7 (4.2) 26.6 (4.2) 26.9 (4.2)
Diabetes, n(%) 85 (11.2) 128(7.3) 99 (12.2) 524 (10.5)
Lung function (FEV1/FVC b70%), n(%) n.a. n.a. n.a. n.a.
Behaviour
Physical activity score at baseline
Inactive, n(%) n.a. n.a. n.a. n.a.
Occasional/Light, n(%) n.a. n.a. n.a. n.a.
From moderately to vigorously active, n(%) n.a. n.a. n.a. n.a.
Smoking
Never, n(%) 205 (27.0) 586 (33.3) 238 (29.4) 1731 (34.7)
Former, n(%) 340 (44.7) 681 (38.7) 357 (44.1) 1920 (38.4)
Current, n(%) 215 (28.3) 493 (28.0) 215 (26.5) 1343 (26.9)
Alcohol consumption
None, n(%) 352 (46.3) 841 (47.8) 378 (46.7) 2198 (44.0)
Occasional (b1 drink/week), n(%) 168 (22.1) 406 (23.1) 168 (20.7) 1175 (23.5)
Light (1–15/week), n(%) 239 (31.4) 511 (29.0) 260 (32.1) 1612 (32.3)
Moderate/regular (16–42/weeks), n(%) 1 (0.1) 2 (0.1) 4 (0.5) 9 (0.2)
Heavy (N42/week), n(%) 0 (0) 0 (0) 0 (0) 0 (0)
Unclassiﬁed, n(%) 0 (0) 0 (0) 0 (0) 0 (0)
House/accommodation
Owner occupier, are you:
An owner occupier, n(%) n.a. n.a. n.a. n.a.
Does your home have
Central heating (yes), n(%) n.a. n.a. n.a. n.a.
Double Glazing (yes/in part), n(%) n.a. n.a. n.a. n.a.
Personal circumstances
Marital status
Married (yes), n(%) n.a. n.a. n.a. n.a.
Working status
Retired, n(%) n.a. n.a. n.a. n.a.
Living conditions
Living alone, n(%) 350 (46.1) 747 (42.4) 329 (40.6) 1988 (39.8)
Car ownership (Yes/No)
Yes, n(%) n.a. n.a. n.a. n.a.
Use of medication (yes)
Anti-coagulants, Warfarin, n(%) 7 (0.9) 7 (0.4) 6 (0.7) 31 (0.6)
Aspirin, n(%) 347 (45.6) 613 (34.8) 390 (48.1) 1714 (34.3)
Beta-adrenoceptor blocking drugs, n(%) 201 (26.4) 412(23.4) 229 (28.3) 1273 (25.5)
Statin, n(%) 369 (48.6) 891 (50.6) 392 (48.4) 2499 (50.0)
ACE-inhibitors, n(%) 82 (10.8) 184 (10.4) 139 (17.2) 812 (16.3)
A-II receptor antagonists, n(%) 13 (1.7) 13 (0.7) 21 (2.6) 95 (1.9)
Diuretics, n(%) 316 (41.6) 729 (41.4) 350 (43.2) 2008 (40.2)
Calcium channel blockers, n(%) 247 (32.5) 537 (30.5) 246 (30.4) 1212 (24.3)
Nitrates, n(%) 247 (32.5) 364 (20.7) 248 (30.6) 843 (16.9)
Other antihypertensive, n(%) 29 (3.8) 53 (3.0) 41 (5.1) 196 (3.9)
Blood glucose lowering: insulin, n(%) 5 (0.7) 7 (0.4) 7 (0.9) 44 (0.9)
Blood glucose lowering: oral hypoglycaemics, n(%) 47 (6.2) 62 (3.5) 56 (6.9) 303 (6.1)
Established CVD risk factors
Systolic blood pressure, mm Hg, mean (SD) 155.5 (22.4) 152.7 (20.7) 155.1 (23.2) 154.6 (21.6)
Diastolic blood pressure, mm Hg, mean (SD) 82.7 (11.5) 82.6 (10.6) 82.3 (12.0) 84.0 (11.3)
Total cholesterol, mmol/L, mean (SD) 5.63 (0.93) 5.72 (0.95) 5.67 (0.88) 5.68 (0.91)
LDL-cholesterol, mmol/L, mean (SD) 3.78 (0.80) 3.83 (0.83) 3.80 (0.80) 3.79 (0.80)
HDL-cholesterol, mmol/L, mean (SD) 1.25 (0.34) 1.31 (0.36) 1.25 (0.35) 1.28 (0.35)
Triglycerides, mmol/L, mean (SD) 1.58 (0.70) 1.56 (0.70) 1.55 (0.68) 1.54 (0.71)
278 C. Sartini et al. / International Journal of Cardiology 218 (2016) 275–283(fatal stroke or CHD death); (ii) CHD death; (iii) earliest of fatal/
non-fatal stroke or CHD death/non-fatal MI; (iv) MI events (earliest
nonfatal MI or CHD death). Risk ratios were stronger for cold spells
of ≥4 days than of ≥3 days and independent of mean temperature
over the previous 6 days (lag 0–6). Estimates were similar and still
signiﬁcant when cold spells of ≥4 days was adjusted for meantemperature on the day itself (lag 0), over the previous day (lag
0–1) and the previous three days (lag 0–3). Therefore, Table 3 re-
ports the estimates adjusted for temperature over the previous
6 days only.
No associations were found between cold spells and any of the
various CVD end-points during the PROSPER follow-up period.
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279C. Sartini et al. / International Journal of Cardiology 218 (2016) 275–283However, there was weak evidence that cold spells of ≥3 days affected
all-cause mortality [RR = 1.28 (0.99, 1.65)].
Pooling the effects on non-fatal or fatal events across studies yielded
an odds ratio of 1.50 (95% CI 1.11 to 2.02, p = 0.008): however there
was evidence of heterogeneity between studies (I2 = 78%, p = 0.03).
3.4. Associations (main effect) between mean temperature and cardiovas-
cular events
Associations were noted between mean temperature and develop-
ment of CVD events in the BRHS study only (Table 4). Associations
were found between a decrease in mean temperature, at both lag 0–3
and lag 0–6, and the following end-points: (i) earliest of fatal/non-
fatal stroke or CHD death/non-fatal MI; (ii) MI events (earliest non-
fatal MI or CHD death), and (iii) stroke events (earliest non-fatal or
fatal stroke). Moreover, the effect of temperature at lag 0–3 was
independent of cold spells (≥3 days) for (i) earliest of fatal/non-fatal
stroke or CHD death/non-fatal MI, and (iii) stroke events (earliest
non-fatal or fatal stroke).
No associations were found between temperature and the different
end-points during the PROSPER follow-up period.
3.5. BRHS follow-up: interactions between cold spells effect and individual
risk factors
Table 5 shows the interactions between cold spells of different
durations and individual risk factors on earliest of either non-fatal/
fatal MI/Stroke for BRHS only. There were suggestions of increased sus-
ceptibility to cold spells (of both ≥3 and ≥4 days of duration) in relation
to smoking status: BRHS men experiencing a cold spell who were cur-
rent/former smokers showed a higher risk of a CVD event than never
smokers (2.79 vs 0.58, interaction test: p = 0.019 for cold spell
≥4 days of duration; 2.44 vs 0.97, interaction test: p = 0.034 for cold
spell ≥3 days of duration). Moreover, there were suggestions of
increased susceptibility to cold spells for the following groups: men
who consumed alcohol more than occasionally vs others (OR 3.29 vs
1.34, interaction test: p = 0.039 for cold spell of ≥4 days), car owners
(OR 2.44 vs 0.94, interaction test: p = 0.035 for cold spell of ≥3 days),
and men who developed an event in winter, between December and
March (RR = 3.28 vs 1.25, interaction test: p = 0.004 for cold spell of
≥3 days).
Given the differences in effects of cold spells between BRHS and
PROSPER, and the vast difference in initial statin usage between the
two studies, we investigated whether statin users seemed to be
protected from cold spells. There was no evidence of interaction
between cold spells and statin use on CVD events in either study. How-
ever there was weak evidence of interaction for all-cause mortality in
PROSPER with the relative risk for 3-day cold spells being 1.28 for
those assigned to placebo and 0.69 for those assigned to statins (p-
for-interaction = 0.043).
4. Discussion
Using data from the British Regional Heart Study (BRHS), we have
demonstrated the effect of cold spells of weather over at least 3 or
4 days on incidence of cardiovascular disease. A 4 day spell increased
risk more than two-fold. This ﬁnding was independent of the actual
temperature level over periods up to twoweeks prior to an event occur-
ring. Effects appeared fairly similar among all subdivisions of the
endpoint, including stroke and coronary events, both fatal and non-
fatal, but were particularly strong for coronary heart disease events.
Furthermore we found that the strength of the effect was greater
among smokers, possibly among those with moderate or greater
alcohol consumption, and during winter months. The effect appeared
to be greater among those who owned a car.
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280 C. Sartini et al. / International Journal of Cardiology 218 (2016) 275–283The analysis of the BRHS includedmenwhose age at baseline ranged
from 60 to 79 years and were followed for an average exceeding
12 years. Themen lived across a full geographical range of Great Britain
(England, Wales and Scotland), representing the well-documented
national variation in cardiovascular mortality rates [18]. Analysis was
based on CVD events in 921 participants, and this gave sufﬁcient statis-
tical power to demonstrate increased risk following three or four day
cold spells. Power to demonstrate effectmodiﬁcationwas however lim-
ited and while some factors were shown to increase the magnitude of
the effect of cold weather spells, these barely reached statistical signiﬁ-
cance at the 5% level. Of note, despite repeated consistent ﬁndings that
older people have sharper excess winter mortality than younger people
[5], the expecteddifferences in relative risks between younger and older
men in BRHS did not emerge as statistically signiﬁcant.
Those factors where suggestion of effect modiﬁcation was closest to
statistical signiﬁcance included smoking and alcohol consumption.
Smoking and alcohol intake may have enhanced vaso-constriction and
led to blood pressure changes, which have been suggested as partly re-
sponsible for excess winter mortality from cardiovascular disease [24,
25]. Participants who owned a car appeared particularly susceptible to
coldweather in comparisonwith participantswhowere not car owners.
However in general car ownership was associated with lower CVD inci-
dence in BRHS: men who owned a car were more likely to be of non-
manual social class, younger, employed rather than retired, and more
physically active; although more likely to use aspirin. Individual expo-
sure to trafﬁc air pollution data was not available in this study and it is
unclear whether or not this may have an impact on those who devel-
oped an event. Finally, although the effect of cold spells appeared to
operate independently from that of cold temperature, it was clear that
cold spells had more effect in winter months.
We carried out similar analysis on data from the PROSPER study
which included men and women aged over 70 at baseline. Similarly to
the BRHS and accordinglywith previous ﬁndings and national mortality
statistics [4], a higher number of fatal CVD events and deaths from all-
causes were registered during winter months in PROSPER. However,
in PROSPER neither effect of cold spells nor of average temperature
was observed on the outcomes. By adding PROSPER data to that of
BRHS it was hoped to conﬁrm and extend the BRHS ﬁndings using a
large study of older adults residing in three areas inside and outside
the UK but with similar latitude and climate (Glasgow, Cork, and Lei-
den). The PROSPER analysis would have allowed estimation of the effect
of cold spells with greater precision, and test whether effects held for
women as well as men. However no associations between cold spells
and CVD events were seen in PROSPER either in men or women, and
these results differed signiﬁcantly from BRHS. By study design, the
PROSPER study excluded people who were abusers of alcohol [19] and
the resulting level of alcohol use was lower among PROSPER partici-
pants than in BRHS. The smoking rate was also lower and it is possible
that the PROSPER participants were thus less susceptible to CVD events
following cold spells. Several cardiovascular medications were used
more frequently by PROSPER participants but the greatest difference
was in statin use, as 50% of PROSPER participants were assigned to prav-
astatin as part of the trial, whereas less than 10% of BRHS participants re-
ported statin use at baseline. However in neither studywas a signiﬁcant
interaction in the effect of cold spells on CVD events according to statin
usage.
4.1. Strengths
To our knowledge, this is the ﬁrst analysis that has employed the
concept of cold spells as opposed to temperature levels. Given the
repeated ﬁnding that excess winter mortality is seen even in countries
with relatively warm climate [4,6,8], we hypothesised that relative
cold was more important than absolute cold. It was therefore possible
that temperature that was cold for the time of year had more impact.
We have demonstrated in the BRHS that although temperature level
Table 3
Effect of cold spells on events. BRHS and PROSPER. The statistically signiﬁcant results are marked in bold.
BRHS follow up period: from Jan
1998–Dec 2012
Cold spell of 3+ days Cold spell of 3+ days
adjusted for mean
temperature lag 0–6
Cold spell of 4+
days
Cold spell of 4+ days
adjusted for mean
temperature lag 0–6
Mortality RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI)
All causes of death, n = 1705 1.09 (0.82,1.43) 1.09 (0.81,1.47) 1.14 (0.81,1.62) 1.15 (0.80,1.67)
CHD death + Fatal Stroke, n = 521 1.62 (1.03,2.55) 1.62 (0.98,2.67) 1.92 (1.11,3.33) 1.93 (1.06,3.52)
CHD death, n = 391 1.76 (1.05,2.95) 1.70 (0.95,3.02) 2.41 (1.30,4.48) 2.38 (1.21,4.69)
Fatal Stroke, n = 130 1.24 (0.47,3.24) 1.37 (0.48,3.88) 0.86 (0.24,3.16) 0.91 (0.23,3.64)
Non-fatal or fatal events
Earliest of either non-fatal/fatal MI/Stroke, n = 921 2.05 (1.49,2.83) 1.86 (1.30,2.65) 2.21 (1.47,3.32) 1.91 (1.23,2.97)
Earliest of non-fatal MI or CHD death, n = 616 2.23 (1.51,3.28) 2.14 (1.39,3.28) 2.86 (1.75,4.69) 2.70 (1.58,4.60)
Earliest of non-fatal/fatal stroke, n = 372 1.69 (0.99,2.89) 1.46 (0.82,2.62) 1.40 (0.69,2.81) 1.13 (0.54,2.38)
PROSPER follow up period: from Dec 1997–June 2009 Cold spell of 3+ days Cold spell of 3+ days
adjusted for mean
temperature lag 0–6
Cold spell of 4+ days Cold spell of 4+ days
adjusted for mean
temperature lag 0–6
Mortality RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI)
All causes of death, n = 2463 1.28 (0.99,1.65) 1.27 (0.96,1.67) 1.16 (0.81,1.64) 1.12 (0.77,1.62)
CHD death + Fatal Stroke, n = 810 1.13 (0.74,1.73) 1.11 (0.70,1.77) 0.72 (0.37,1.39) 0.67 (0.34,1.33)
CHD death, n = 582 1.10 (0.67,1.82) 1.14 (0.66,1.96) 0.74 (0.34,1.58) 0.73 (0.33,1.62)
Fatal Stroke, n = 228 1.22 (0.53,2.78) 1.05 (0.43,2.59) 0.68 (0.19,2.40) 0.53 (0.14,2.01)
Non-fatal or fatal events
Earliest of either non-fatal/fatal MI/Stroke,
Glasgow participants, n = 760
0.99 (0.59,1.65) 0.91 (0.53,1.57) 1.04 (0.52,2.10) 0.95 (0.46,1.98)
Earliest of non-fatal MI or CHD death,
Glasgow participants, n = 435
1.23 (0.67,2.27) 1.07 (0.55,2.08) 1.25 (0.56,2.78) 1.06 (0.46,2.48)
Earliest of non-fatal/fatal stroke,
Glasgow participants, n = 358
0.75 (0.33,1.72) 0.75 (0.32,1.79) 1.16 (0.43,3.18) 1.22 (0.43,3.50)
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pact of cold spells over 3 or 4 days. Moreover, a main strength was the
analysis of the effect of cold spells by established cardiovascular risk
factors (e.g. age and smoking) and previously unexplored individual
characteristics (e.g. physical activity score, central heating and double
glazing in the house).Table 4
Effect of temperature on events for BRHS and PROSPER. The statistically signiﬁcant results are
BRHS follow up
period: from Jan 1998–Dec
2012
Decrease of 1 °C in
mean temperature,
cumulative lag 0–3
D
te
la
sp
Mortality RR (95% CI) R
All causes of death, n = 1705 0.99 (0.97,1.02) 0
CHD death + Fatal Stroke, n = 521 1.02 (0.98,1.06) 1
CHD death, n = 391 1.03 (0.98,1.08) 1
Fatal Stroke, n = 130 0.99 (0.91,1.07) 0
Non-fatal or fatal events
Earliest of either non-fatal/fatal MI/Stroke, n = 921 1.06(1.03,1.08) 1
Earliest of non-fatal MI or CHD death, n = 616 1.04(1.01,1.08) 1
Earliest of non-fatal/fatal stroke, n = 372 1.07(1.02,1.12) 1
PROSPER follow up period: from Dec 1997–June 2009 Decrease of 1 °C in
mean temperature,
cumulative lag 0–3
De
te
la
sp
Mortality RR (95% CI) RR
All causes of death, n = 2463 1.00 (0.98,1.03) 0.
CHD death + Fatal Stroke, n = 810 1.01 (0.97,1.05) 1.
CHD death, n = 582 1.00 (0.96,1.05) 1.
Fatal Stroke, n = 228 1.02 (0.95,1.10) 1.
Non-fatal or fatal events
Earliest of either non-fatal/fatal MI/Stroke,
Glasgow participants, n = 760
1.01 (0.97,1.05) 1.
Earliest of non-fatal MI or CHD death,
Glasgow participants, n = 435
1.03 (0.98,1.09) 1.
Earliest of non-fatal/fatal stroke,
Glasgow participants, n = 358
0.99 (0.93,1.05) 1.4.2. Limitations
Not all fatal events in BRHS or PROSPER represented sudden deaths
and for some individuals, a non-fatal eventmay still have occurred up to
28 days previously [19,26,27]. The exact date of such events was not
known and thus our analysis refers to weather at the time of themarked in bold.
ecrease of 1 °C in mean
mperature, cumulative
g 0–3 adjusted for cold
ell of 3+ days
Decrease of 1 °C in
mean temperature,
cumulative lag 0–6
Decrease of 1 °C in mean
temperature, cumulative
lag 0–6 adjusted for cold
spell of 3+ days
R (95% CI) RR (95% CI) RR (95% CI)
.99 (0.96,1.02) 1.00 (0.98,1.03) 1.00 (0.97,1.03)
.00 (0.96,1.05) 1.02 (0.97,1.07) 1.00 (0.95,1.05)
.01 (0.96,1.06) 1.03 (0.98,1.08) 1.00 (0.94,1.06)
.98 (0.89,1.07) 0.99 (0.88,1.08) 0.99 (0.88,1.09)
.03(1.00,1.07) 1.05(1.01,1.08) 1.02(0.98,1.06)
.01(0.97,1.05) 1.04(1.00,1.08) 1.01(0.96,1.05)
.06(1.01,1.11) 1.05(0.99,1.10) 1.03(0.97,1.09)
crease of 1 °C in mean
mperature, cumulative
g 0–3 adjusted for cold
ell of 3+ days
Decrease of 1 °C in
mean temperature,
cumulative lag 0–6
Decrease of 1 °C in
mean temperature,
cumulative lag 0–6 adjusted
for cold spell of 3+ days
(95% CI) RR (95% CI) RR (95% CI)
99 (0.97,1.02) 1.01 (0.98,1.04) 1.00 (0.97,1.03)
00 (0.96,1.05) 1.01 (0.96,1.06) 1.00 (0.96,1.05)
00 (0.95,1.05) 1.00 (0.94,1.05) 0.99 (0.93,1.05)
01 (0.93,1.10) 1.04 (0.96,1.13) 1.04 (0.95,1.14)
01 (0.97,1.06) 1.02 (0.97,1.07) 1.02 (0.97,1.07)
03 (0.97,1.10) 1.04 (0.98,1.11) 1.04 (0.97,1.11)
00 (0.94,1.06) 0.99 (0.93,1.06) 1.00 (0.93,1.07)
Table 5
BRHS participants. Interactions between cold spells of different durations and individual characteristics on earliest of either non-fatal/fatal MI/Stroke. P-values b0.05 are marked in bold.
Earliest of either non-fatal/fatal MI/Stroke N Cold spell 3+ days
RR (95% CI)
p-Value for interaction Cold spell 4+ days
RR (95% CI)
p-Value for interaction
Age b 70 428 1.83 (1.12,2.99) 0.547 1.93 (1.02,3.64) 0.579
Age N=70 493 2.24 (1.46,3.43) 2.44 (1.43,4.15)
Non-Manual social class 397 2.69 (1.64,4.40) 0.229 2.73 (1.46,5.10) 0.520
Manual social class 488 1.80 (1.16,2.78) 2.07 (1.20,3.59)
Previous stroke/MI, No 763 2.07 (1.47,2.91) 0.867 2.25 (1.45,3.47) 0.846
Previous stroke/MI, Yes 158 1.90 (0.72,5.03) 1.99 (0.63,6.26)
Normal weight (BMI 18.5–25) 261 1.81 (0.99,3.30) 0.625 2.31 (1.08,4.93) 0.898
Underweight or overweight 653 2.16 (1.48,3.16) 2.17 (1.34,3.52)
Diabetes, No 784 2.05 (1.45,2.90) 0.977 2.15 (1.36,3.38) 0.767
Diabetes, Yes 137 2.07 (0.90,4.78) 2.51 (1.00,6.30)
COPD: NO (FEV1/FEVC ≥ 70%) 693 1.99 (1.38,2.87) 0.884 2.18 (1.38,3.44) 0.893
COPD: YES (FEV1/FEVC b 70%) 214 2.11 (1.06,4.17) 2.03 (0.80,5.17)
Physical activity: light/occasional/inactive 525 2.04 (1.29,3.22) 0.756 1.80 (1.03,3.15) 0.428
Physical activity: from moderate to vigorous 352 1.83 (1.13,2.99) 2.55 (1.33,4.89)
Non-smoker 233 0.97 (0.45,2.10) 0.034 0.58 (0.17,1.99) 0.019
Smoker or ex-smoker 684 2.44 (1.70,3.50) 2.79 (1.77,4.38)
Occasional or non-drinker 390 1.41 (0.82,2.42) 0.080 1.34 (0.70,2.58) 0.039
Light/Moderate/Heavy drinker 506 2.59 (1.71,3.92) 3.29 (1.91,5.67)
Owner occupier 745 2.16 (1.51,3.09) 0.317 2.39 (1.50,3.81) 0.352
Renting from the local authority 112 1.30 (0.52,3.27) 1.37 (0.47,4.01)
Central heating: Yes 807 2.18 (1.55,3.07) 0.329 2.48 (1.60,3.83) 0.182
Central Heating: No 114 1.32 (0.51,3.42) 1.04 (0.31,3.45)
Double glazing: No 404 2.20 (1.44,3.35) 0.626 2.77 (1.63,4.71) 0.199
Double glazing: Yes/in part 517 1.87 (1.13,3.07) 1.60 (0.84,3.07)
Married 721 2.17 (1.49,3.16) 0.378 2.50 (1.55,4.01) 0.195
Single/divorced/separated/widowed/other 160 1.53 (0.77,3.03) 1.24 (0.49,3.18)
Retired 106 1.94 (1.37,2.76) 0.716 2.04 (1.31,3.17) 0.873
Employed 778 1.60 (0.61,4.23) 1.81 (0.45,7.27)
Living alone 128 1.88 (0.89,3.98) 0.839 1.84 (0.68,4.98) 0.719
Living with others 765 2.05 (1.42,2.94) 2.25 (1.42,3.54)
Car owner: Yes 705 2.44 (1.70,3.51) 0.035 2.84 (1.77,4.55) 0.053
Car owner: No 194 0.94 (0.42,2.11) 1.01 (0.40,2.58)
Regular use of aspirin: No 557 1.78 (1.17,2.71) 0.299 1.76 (1.03,3.01) 0.182
Regular use of aspirin: Yes 358 2.52 (1.53,4.14) 3.11 (1.64,5.88)
Use of Beta Blockers: No 771 2.00 (1.42,2.83) 0.721 1.99 (1.27,3.12) 0.256
Use of Beta Blockers: Yes 150 2.37 (1.00,5.60) 3.77 (1.38,10.29)
Use of statin: No 820 2.11 (1.51,2.96) 0.573 2.32 (1.51,3.55) 0.506
Use of statin: Yes 101 1.53 (0.52,4.48) 1.42 (0.36,5.66)
Region: South/Midlands 413 2.11 (1.28,3.45) 0.892 1.53 (0.78,3.00) 0.164
Region: North/Scotland 508 2.01 (1.32,3.07) 2.79 (1.66,4.69)
Non winter months 556 1.25 (0.77,2.03) 0.004 1.42 (0.69,2.91) 0.128
Winter months (Dec–Mar) 365 3.28 (2.09,5.13) 2.81 (1.70,4.64)
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might have led to a diluted estimate of the true association between
cold spells and CVD incidence, especially when analysing fatal events
alone. However a Swedish study has suggested that a minority of fatal
CHD events occur inside hospital and this proportion has decreased
over time [28].
Compared to the BRHS, the exposure assessment to outdoor temper-
ature in PROSPERwas less accurate for two reasons: (i) PROSPER partic-
ipants were recruited from wide areas around Glasgow, Cork and
Leiden, and matched with the only weather station available in town
(while in the BRHS the participants living in 24 UK towns and their sur-
roundings were matched with the closest of 35 weather stations via
postcode); (ii) as postcode of residence was not available in PROSPER,
it is not known whether or not the participants changed town of resi-
dence or sub-region to during the study period (differently, only BRHS
participants who did not change postcode of residence were
included). Therefore, a misclassiﬁcation of exposure to outdoor
temperature was possible and the estimates may be less accurate in
PROSPER.
4.3. Implications
Our study conﬁrmed an excess of winter mortality from CVD and
also susceptibility to cold spells in the BRHS population. The role ofcold spells and cold weather continue to be debated, and this study
added new evidence that vulnerable subgroups of older men may be
particularly exposed to the effects of cold weather, and prolonged spells
of unusual degrees of cold for the timeof yearmight be particularly haz-
ardous. Recent guidance from the UK National Institute for Health Care
and Excellence [29] made a key recommendation concerning the
establishment of a single point-of-contact referral service for vulnerable
older people living in cold homes. Primary care team practitioners
(including GPs, community matrons and district nurses) as well as so-
cial care professionals have been asked to identify the heating needs
of vulnerable people and refer them where appropriate. However the
means by which the recommendation can practically be achieved now
needs to be evaluated for its impact on theUK's persisting excesswinter
mortality.
5. Conclusions
A higher number of CVD events occurred during winter months in
both BRHS and PROSPER prospective studies. However, cold spells
increased risk of CVD events, and independently of cold temperature,
in the BRHS only, a population-based study representative of older
men in Great Britain. Some health behaviours may have made BRHS
men more susceptible. Strategies to avoid excess winter mortality due
to CVD should account for the impact of generally low temperature
283C. Sartini et al. / International Journal of Cardiology 218 (2016) 275–283coupledwith particularly cold spells. This study also highlighted the im-
portance of accurate assessment of exposure to outdoor temperature,
for more accurate estimates of a cold spell effect.
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